Neurocrine Biosciences
Delaware corporation
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
Source: Wikipedia · CC BY-SA 4.0
last observed
Activity Score
—
not enough monitored evidence
Hiring Momentum 30d
—
not enough monitored evidence
Product Velocity
—
not enough monitored evidence
AI Adoption
—
not enough monitored evidence
Corporate Change Index
—
not enough monitored evidence
9 active sensors·0 observations·0 historical changes·0 structured events
Compare Neurocrine Biosciences with peers on activity, hiring, product velocity, AI adoption, locations and events.
Compare companies